Biotech Co. Human Genome Rejects $2.6B Bid From GSK
Human Genome said the $13 per-share offer “does not reflect value inherent” in the company, and added it would explore its options, including a possible sale of the company. It invited Glaxo to participate in the exploratory process, which it has retained Goldman Sachs and Credit Suisse to help run.
“Having worked together...
To view the full article, register now.